First-in-Class: Recombinant Human Albumin Injection (Oryza Sativa) Approved by China NMPA

Source:Posted by Themecurve| Time:2025-07-18| Hits:69

Healthgens Recombinant Human Albumin Injection(Oryza Sativa) was approved by the Chinas National Medical Products Administration (NMPA)on 18 July, 2025.

 

Drug Name: Recombinant Human Albumin Injection (Oryza Sativa)

Drug Approval No.: National Drug Approval No.S20250039

Indications: Hypoproteinemia

Packing: 10g(20%,50mL)

Author:Site editorEdit:Site editor
Share

Wuhan Healthgen Biotechnology Corp.

Tel. 027-59403931 Ext 8009

WhatsApp. +86-13971194951

268 Shendun 5th Road, East Lake High-Tech Development Zone, Wuhan, China 430020

Copyright ® Wuhan Healthgen Biotechnology Corp. All rights reserved. Terms and Conditions of Use
鄂ICP备12013293号-3